Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Enhanced detection of circulating tumor DNA by fragment size analysis.

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Østrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sørensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N.

Sci Transl Med. 2018 Nov 7;10(466). pii: eaat4921. doi: 10.1126/scitranslmed.aat4921.

PMID:
30404863
2.

Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence.

O'Reilly D, Fou L, Hasler E, Hawkins J, O'Connell S, Pelone F, Callaway M, Campbell F, Capel M, Charnley R, Corrie P, Elliot D, Goodburn L, Jewell A, Joharchi S, McGeeney L, Mukherjee S, Oppong K, Whelan P, Primrose J, Neoptolemos J.

Pancreatology. 2018 Sep 28. pii: S1424-3903(18)30689-6. doi: 10.1016/j.pan.2018.09.012. [Epub ahead of print] Review.

PMID:
30292643
3.

Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.

Casey RT, Giger O, Seetho I, Marker A, Pitfield D, Boyle LH, Gurnell M, Shaw A, Tischowitz M, Maher ER, Chatterjee VK, Janowitz T, Mells G, Corrie P, Challis BG.

Semin Oncol. 2018 Jun 21. pii: S0093-7754(18)30125-8. doi: 10.1053/j.seminoncol.2018.06.001. [Epub ahead of print]

4.

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.

Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, Barker E, Newton-Bishop J, Middleton MR, Corrie PG.

Br J Cancer. 2018 Oct;119(7):793-800. doi: 10.1038/s41416-018-0179-6. Epub 2018 Jul 23.

5.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR; AVAST-M Investigators .

Ann Oncol. 2018 Aug 1;29(8):1843-1852. doi: 10.1093/annonc/mdy229.

6.

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.

Backen AC, Lopes A, Wasan H, Palmer DH, Duggan M, Cunningham D, Anthoney A, Corrie PG, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, McNamara MG, Beare S, Bridgewater JA, Dive C, Valle JW.

Br J Cancer. 2018 Jul;119(1):27-35. doi: 10.1038/s41416-018-0132-8. Epub 2018 Jun 21.

PMID:
29925934
7.

Expert Elicitation of Multinomial Probabilities for Decision-Analytic Modeling: An Application to Rates of Disease Progression in Undiagnosed and Untreated Melanoma.

Wilson ECF, Usher-Smith JA, Emery J, Corrie PG, Walter FM.

Value Health. 2018 Jun;21(6):669-676. doi: 10.1016/j.jval.2017.10.009. Epub 2017 Dec 8.

PMID:
29909871
8.

A Modeling Study of the Cost-Effectiveness of a Risk-Stratified Surveillance Program for Melanoma in the United Kingdom.

Wilson ECF, Usher-Smith JA, Emery J, Corrie P, Walter FM.

Value Health. 2018 Jun;21(6):658-668. doi: 10.1016/j.jval.2017.11.009. Epub 2018 Apr 11.

PMID:
29909870
9.

HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.

Doherty GJ, Tempero M, Corrie PG.

Future Oncol. 2018 Jan;14(1):13-22. doi: 10.2217/fon-2017-0338. Epub 2017 Oct 23.

PMID:
29235360
10.

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.

Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R.

Ann Oncol. 2018 Feb 1;29(2):490-496. doi: 10.1093/annonc/mdx717.

11.

Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury.

Doherty GJ, Duckworth AM, Davies SE, Mells GF, Brais R, Harden SV, Parkinson CA, Corrie PG.

ESMO Open. 2017 Oct 10;2(4):e000268. doi: 10.1136/esmoopen-2017-000268. eCollection 2017.

12.

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.

Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP.

Lancet Oncol. 2017 Apr;18(4):486-499. doi: 10.1016/S1470-2045(17)30084-0. Epub 2017 Mar 2.

PMID:
28259610
13.

Genomic analysis and clinical management of adolescent cutaneous melanoma.

Rabbie R, Rashid M, Arance AM, Sánchez M, Tell-Marti G, Potrony M, Conill C, van Doorn R, Dentro S, Gruis NA, Corrie P, Iyer V, Robles-Espinoza CD, Puig-Butille JA, Puig S, Adams DJ.

Pigment Cell Melanoma Res. 2017 May;30(3):307-316. doi: 10.1111/pcmr.12574. Epub 2017 Apr 19.

14.

Lesson of the month 2: Cauda equina in Cushing's syndrome.

Maslin D, Gounaris I, Ng K, Corrie P.

Clin Med (Lond). 2016 Feb;16(1):88-90. doi: 10.7861/clinmedicine.16-1-88.

PMID:
26833526
15.

Withdrawal of anticancer therapy in advanced disease: a systematic literature review.

Clarke G, Johnston S, Corrie P, Kuhn I, Barclay S.

BMC Cancer. 2015 Nov 11;15:892. doi: 10.1186/s12885-015-1862-0. Review.

16.

Evolving treatment options for melanoma brain metastases.

Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S.

Lancet Oncol. 2015 Oct;16(13):e486-97. doi: 10.1016/S1470-2045(15)00141-2. Review.

PMID:
26433822
17.

Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.

Ghorani E, Wong HH, Hewitt C, Calder J, Corrie P, Basu B.

Oncology. 2015;89(5):281-7. doi: 10.1159/000439171. Epub 2015 Sep 16.

PMID:
26372905
18.

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.

Ahmad SS, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K, Rao A, Board R, Nobes J, Dalgleish A, Grumett S, Maraveyas A, Danson S, Talbot T, Harries M, Marples M, Plummer R, Kumar S, Nathan P, Middleton MR, Larkin J, Lorigan P, Wheater M, Ottensmeier CH, Corrie PG.

Melanoma Res. 2015 Oct;25(5):432-42. doi: 10.1097/CMR.0000000000000185.

19.

Unmet clinical needs in the management of advanced melanoma: findings from a survey of oncologists.

Jones C, Clapton G, Zhao Z, Barber B, Saltman D, Corrie P.

Eur J Cancer Care (Engl). 2015 Nov;24(6):867-72. doi: 10.1111/ecc.12359. Epub 2015 Jul 29.

20.

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA.

Lancet Oncol. 2015 Aug;16(8):967-78. doi: 10.1016/S1470-2045(15)00139-4. Epub 2015 Jul 12. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.

21.

Seasonal variation in diagnosis of invasive cutaneous melanoma in Eastern England and Scotland.

Walter FM, Abel GA, Lyratzopoulos G, Melia J, Greenberg D, Brewster DH, Butler H, Corrie PG, Campbell C.

Cancer Epidemiol. 2015 Aug;39(4):554-61. doi: 10.1016/j.canep.2015.06.006. Epub 2015 Jul 2.

22.

Treatment patterns in advanced melanoma: findings from a survey of European oncologists.

Jones C, Zhao Z, Barber B, Bagijn M, Corrie P, Saltman D.

Eur J Cancer Care (Engl). 2015 Nov;24(6):862-6. doi: 10.1111/ecc.12326. Epub 2015 May 18.

PMID:
25988349
23.

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.

Welsh SJ, Corrie PG.

Ther Adv Med Oncol. 2015 Mar;7(2):122-36. doi: 10.1177/1758834014566428. Review.

24.

Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.

Elias A, Chatzizacharias NA, Xanthis A, Corrie P, Davies S, Brais RJ, Jamieson NV, Praseedom RK, Huguet E, Harper SJ, Jah A.

Medicine (Baltimore). 2015 Feb;94(6):e499. doi: 10.1097/MD.0000000000000499.

25.

Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma.

Cook N, Brais R, Qian W, Hak CC, Corrie PG.

J Clin Pathol. 2015 Apr;68(4):309-13. doi: 10.1136/jclinpath-2014-202521. Epub 2015 Jan 8.

PMID:
25572612
26.

PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.

Coupe N, Corrie P, Hategan M, Larkin J, Gore M, Gupta A, Wise A, Suter S, Ciria C, Love S, Collins L, Middleton MR.

Eur J Cancer. 2015 Feb;51(3):359-66. doi: 10.1016/j.ejca.2014.11.018. Epub 2014 Dec 24.

PMID:
25542057
27.

Pyogenic granuloma as a cutaneous adverse effect of vemurafenib.

Sammut SJ, Tomson N, Corrie P.

N Engl J Med. 2014 Sep 25;371(13):1265-7. doi: 10.1056/NEJMc1407683. No abstract available.

28.

Management of melanoma.

Corrie P, Hategan M, Fife K, Parkinson C.

Br Med Bull. 2014 Sep;111(1):149-62. doi: 10.1093/bmb/ldu019. Review.

PMID:
25190764
29.

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, Cunningham D, Falk S, Wadd N, Harrison M, Corrie P, Iveson T, Robinson A, McAdam K, Eatock M, Evans J, Archer C, Hickish T, Garcia-Alonso A, Nicolson M, Steward W, Anthoney A, Greenhalf W, Shaw V, Costello E, Naisbitt D, Rawcliffe C, Nanson G, Neoptolemos J.

Lancet Oncol. 2014 Jul;15(8):829-40. doi: 10.1016/S1470-2045(14)70236-0. Epub 2014 Jun 19.

PMID:
24954781
30.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P.

Lancet Oncol. 2014 May;15(6):620-30. doi: 10.1016/S1470-2045(14)70110-X. Epub 2014 Apr 15. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Lancet Oncol. 2014 Jun;15(7):e253.

31.

"It can't be very important because it comes and goes"--patients' accounts of intermittent symptoms preceding a pancreatic cancer diagnosis: a qualitative study.

Evans J, Chapple A, Salisbury H, Corrie P, Ziebland S.

BMJ Open. 2014 Feb 18;4(2):e004215. doi: 10.1136/bmjopen-2013-004215.

32.

Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.

Meyer T, Qian W, Caplin ME, Armstrong G, Lao-Sirieix SH, Hardy R, Valle JW, Talbot DC, Cunningham D, Reed N, Shaw A, Navalkissoor S, Luong TV, Corrie PG.

Eur J Cancer. 2014 Mar;50(5):902-11. doi: 10.1016/j.ejca.2013.12.011. Epub 2014 Jan 17.

PMID:
24445147
33.

The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.

Annels NE, Shaw VE, Gabitass RF, Billingham L, Corrie P, Eatock M, Valle J, Smith D, Wadsley J, Cunningham D, Pandha H, Neoptolemos JP, Middleton G.

Cancer Immunol Immunother. 2014 Feb;63(2):175-83. doi: 10.1007/s00262-013-1502-y. Epub 2013 Nov 29.

PMID:
24292263
34.

Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009-2010).

Liniker E, Harrison M, Weaver JM, Agrawal N, Chhabra A, Kingshott V, Bailey S, Eisen TG, Corrie PG.

Br J Cancer. 2013 Oct 15;109(8):2051-7. doi: 10.1038/bjc.2013.495. Epub 2013 Sep 24.

35.

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, Aamdal S, Ascierto PA, Patel PM, Kruit WH, Bastholt L, Borgognoni L, Bernengo MG, Davidson N, Polders L, Praet M, Spatz A.

J Clin Oncol. 2013 Oct 20;31(30):3831-7. doi: 10.1200/JCO.2012.47.9303. Epub 2013 Sep 9.

PMID:
24019551
36.

Is community treatment best? a randomised trial comparing delivery of cancer treatment in the hospital, home and GP surgery.

Corrie PG, Moody AM, Armstrong G, Nolasco S, Lao-Sirieix SH, Bavister L, Prevost AT, Parker R, Sabes-Figuera R, McCrone P, Balsdon H, McKinnon K, Hounsell A, O'Sullivan B, Barclay S.

Br J Cancer. 2013 Sep 17;109(6):1549-55. doi: 10.1038/bjc.2013.414. Epub 2013 Aug 29.

37.

Inspired to improve outcomes in pancreatic cancer. Interviewed by Natasha Galukande.

Corrie P.

Future Oncol. 2013 Jun;9(6):781-4. doi: 10.2217/fon.13.45. No abstract available.

38.

An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.

Brady J, Corrie P, Chau I, Digumarti R, Adams LM, Botbyl J, Laubscher KH, Midgley RS, Mallath M.

Invest New Drugs. 2013 Oct;31(5):1228-35. doi: 10.1007/s10637-013-9938-7. Epub 2013 Feb 28.

PMID:
23456563
39.

Outcome of second-line chemotherapy for biliary tract cancer.

Bridgewater J, Palmer D, Cunningham D, Iveson T, Gillmore R, Waters J, Harrison M, Wasan H, Corrie P, Valle J.

Eur J Cancer. 2013 Apr;49(6):1511. doi: 10.1016/j.ejca.2012.11.024. Epub 2012 Dec 20. No abstract available.

PMID:
23265701
40.

A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.

Corrie PG, Bulusu R, Wilson CB, Armstrong G, Bond S, Hardy R, Lao-Sirieix S, Parashar D, Ahmad A, Daniel F, Hill M, Wilson G, Blesing C, Moody AM, McAdam K, Osborne M.

Br J Cancer. 2012 Aug 7;107(4):585-7. doi: 10.1038/bjc.2012.318. Epub 2012 Jul 19.

41.

Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials.

Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP, Neesse A, Lockley M, Corrie PG, Jodrell DI, Praseedom RK, Huguet EL, Jah A, Jamieson NV, de Sauvage FJ, Tuveson DA, Carroll NR.

Pancreatology. 2012 Jan-Feb;12(1):8-15. doi: 10.1016/j.pan.2011.12.009. Epub 2011 Dec 31.

PMID:
22487467
42.

The role of angiogenesis inhibitors in the management of melanoma.

Zaki KA, Basu B, Corrie P.

Curr Top Med Chem. 2012;12(1):32-49. Review.

PMID:
22196268
43.

Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain.

Basu B, Correa de Sampaio P, Mohammed H, Fogarasi M, Corrie P, Watkins NA, Smethurst PA, English WR, Ouwehand WH, Murphy G.

Int J Biochem Cell Biol. 2012 Feb;44(2):393-403. doi: 10.1016/j.biocel.2011.11.015. Epub 2011 Nov 26.

PMID:
22138224
44.

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).

Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB; UK and Ireland Neuroendocrine Tumour Society.

Gut. 2012 Jan;61(1):6-32. doi: 10.1136/gutjnl-2011-300831. Epub 2011 Nov 3.

45.

Protocol for the OUTREACH trial: a randomised trial comparing delivery of cancer systemic therapy in three different settings: patient's home, GP surgery and hospital day unit.

Corrie PG, Moody M, Wood V, Bavister L, Prevost T, Parker RA, Sabes-Figuera R, McCrone P, Balsdon H, McKinnon K, O'Sullivan B, Tan RS, Barclay SI.

BMC Cancer. 2011 Oct 29;11:467. doi: 10.1186/1471-2407-11-467.

46.

Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma.

Ahmad S, Lewis M, Corrie P, Iddawela M.

J Oncol Pharm Pract. 2012 Jun;18(2):287-92. doi: 10.1177/1078155211411001. Epub 2011 Aug 1.

PMID:
21807763
47.

Targeting angiogenesis in melanoma: prospects for the future.

Corrie PG, Basu B, Zaki KA.

Ther Adv Med Oncol. 2010 Nov;2(6):367-80. doi: 10.1177/1758834010380101.

48.

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.

Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, Ottensmeier C, Chevreau C, Chao D, Nathan PD, Jouary T, Harries M, Negrier S, Montegriffo E, Ahmad T, Gibbens I, James MG, Strauss UP, Prendergast S, Gore ME.

Br J Cancer. 2011 Jul 26;105(3):353-9. doi: 10.1038/bjc.2011.257. Epub 2011 Jul 12.

49.

A phase 2 study of vatalanib in metastatic melanoma patients.

Cook N, Basu B, Biswas S, Kareclas P, Mann C, Palmer C, Thomas A, Nicholson S, Morgan B, Lomas D, Sirohi B, Mander AP, Middleton M, Corrie PG.

Eur J Cancer. 2010 Oct;46(15):2671-3. doi: 10.1016/j.ejca.2010.07.014. Epub 2010 Aug 25.

PMID:
20800475
50.

Revised UK guidelines for the management of cutaneous melanoma 2010.

Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, Gore ME, Lorigan P, Mackie R, Nathan P, Peach H, Powell B, Walker C; British Association of Dermatologists (BAD) Clinical Standards Unit.

J Plast Reconstr Aesthet Surg. 2010 Sep;63(9):1401-19. doi: 10.1016/j.bjps.2010.07.006. Epub 2010 Aug 21.

PMID:
20728418

Supplemental Content

Loading ...
Support Center